背景：跨膜酪氨酸激酶样孤儿受体1（ROR1）在慢性淋巴细胞性白血病（CLL）细胞的成因和持续性淋巴瘤发生上起作用。本研究旨在探讨CLL细胞中ROR1表面表达水平与疾病发现之间是否存在关系。材料和方法：根据首次诊断时基于流式细胞术分析的CLL患者的ROR1细胞表面表达水平来确定。根据高、低ROR1水平分为两组。通过使用受试者工作特征曲线（ROC曲线）计算高级别疾病的ROR1水平的截断点。统计学显著性定义为双侧p值<0.05。结果：纳入参与者108例CLL病例，中位年龄为60岁。CD5/CD19阳性白血病细胞中ROR1细胞表面标记呈阳性的中位数百分比为62%。高ROR1水平的CLL病例具有血小板减少症（p=0.042）、贫血（p=0.028）和β-2微球蛋白高于等于3 mg/dL（p=0.002）以及需一线治疗（p=0.043）。结论：扩大RAİ分期疾病、需一线治疗、贫血、较高的β-2微球蛋白水平、脾肿大与高水平 ROR1表达在CLL患者中相关。需通过更全面研究CLL病例中ROR1表达水平，来探讨其对预测疾病负担和侵袭性的影响。版权所有© 2023年德黑兰医科大学。

Background: The transmembrane receptor tyrosine kinase-like orphan receptor 1 (ROR1) has acted on the causation and sustentation of mature B-cell lymphomagenesis for chronic lymphocytic leukemia (CLL) cells. The study attempted to show whether there is a relationship between the level of ROR1 surface expression in CLL cells and disease findings. Materials and Methods: The level of ROR1 cell surface expression was determined in accordance with the flow cytometric analysis of CLL patients at the first diagnosis time.  Two groups were formed according to the high and low ROR1 levels. The cut-off point for the ROR1 level was calculated for advanced-stage disease using receiver operating characteristic (ROC) curves. A two-sided p-value <0,05 was considered statistically significant. Results: 108 CLL cases with a median age of 60 were enrolled. The median percentage of ROR1 cell surface marker positivity in the CD5/CD19 positive leukemic cell was 62%. The CLL cases with high ROR1 levels have thrombocytopenia (p=0.042), anemia (p=0.028), and high beta-2 microglobulin value ≥3 mg/dL (p=0.002) and the need for first-line treatment (p=0.043). Conclusion: The poor prognostic parameters such as splenomegaly, anemia, higher beta-2 microglobulin levels, intermediate/advanced RAİ stage disease, and need for first-line treatment had associated high-level ROR 1 expression of our CLL patients. It needs to be investigated for its effect on predicting disease burden and aggressiveness with more comprehensive studies on ROR1 expression levels in CLL cases.Copyright © 2023 Tehran University of Medical Sciences.